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Thalassemia is one of the most common genetic diseases in the world. It is a major health prob-lem, causing much morbidity, early mortality 
and a great deal of misery for a family both financially 
and emotionally. In Egypt, b-thalassemia is the most 
common type with a carrier rate varying from 5.3% to 
≥9% and a gene frequency of 0.03. So, it was estimated 
that 1000/1.5 million per year live births suffer from 
thalassemia disease in Egypt.1
Hepatitis C virus (HCV) infection is a major, world-
wide health problem.1 It is estimated that over 170- 200 
million people are infected and the virus is distributed 
worldwide with a prevalence varying in different coun-
tries from 0.2% up to 40%.2,3 HBV infection occurs 
throughout the world with more than 2 billion people 
infected, and HBV-related deaths occur at a rate of over 
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BACKGROUND AND OBJECTIVES: though regular blood transfusion improves the overall survival of patients 
with b-thalassemia, it carries a definite risk of infection with blood-borne viruses. the present study was car-
ried out to estimate the real frequency of hepatitis B virus (hBV) and hepatitis C virus (hCV) among Egyptian 
b-thalassemic patients, and determine the infection-associated risk factors in these patients. 
DESIGN AND SETTING: a prospective study conducted in a university hospital from January 2009 to January 
2010.
PATIENTS AND METHODS: two hundred patients with b-thalassemia major were enrolled in this study. using 
enzyme-linked immunoabsorbent assay (ELisa), their sera were tested for hepatitis B surface antigen (hBsag), 
antibody to hepatitis C core antigen (anti-hBc), and hCV antibody (hCV ab). the positive hCV ab results were 
confirmed by second generation recombinant immunoblot assay (riBa). 
RESULTS: the study sample consisted of 111 males and 89 females, with a median age of 13 years. Eighty-one 
(40.5%) patients were hCV ab positive by ELisa and 39 (19.5) were anti-hCV positive By riBa; 58 (29.0%) were 
hBsag positive and 13 (6.5%) were anti-hBc positive. older age, an increased number of transfusion units, and 
hBsag seropositivity were significantly associated with a higher prevalence of hCV and hBV. 
CONCLUSION: the prevalence of hCV and hBV infections are very high among Egyptian b-thalassemic patients, 
which calls for a critical look into the prevailing transfusion practices and adoption of stricter donor selection crite-
ria to decrease the incidence rate of both hCV and hBV infections effectively. furthermore, there is a compressing 
need for the use of more specific and sensitive methods for hCV testing in mansoura university hospitals. 
1 million per year.4 According to Egyptian studies, the 
prevalence of HBsAg in Egypt is of intermediate ende-
micity (2%–8%) and nearly 2 to 3 million Egyptians are 
chronic carriers of HBV.5,6
While rigorous donor screening, testing procedures 
and suitable donor selection programs have dramatically 
reduced transmission of HCV via transfusion of blood 
products, there are still many countries where standards 
of blood product management do not adequately pro-
tect chronically-transfused patients especially thalas-
semia patients from this complication.7 b-thalassemia 
major patients are among the high risk groups for blood 
transfusion-related infection.8 The prevalence of HCV 
infection among thalassemic patients ranged from 4.4% 
to 85% in different reports.9 In Egypt, the latest reports 
are one or two decades old and updated data are not 
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available.10 On the other hand no data exist on the over-
all burden of transfusion transmitted HBV in Egyptian 
patients with thalassemia. The present study was un-
dertaken to investigate the true prevalence of HBV and 
HCV in multiply transfused patients with thalassemia 
and to assess HCV infection-associated risk factors in 
these patients.
PATIENTS AND METHODS
A total of 200 patients with a confirmed diagnosis of b-
thalassemia were included in this study. They were 111 
male and 89 female patients who were receiving regular 
transfusion therapy at the Thalassemia Care Center in 
Mansoura University Children’s Hospital, Mansoura, 
Egypt and centers. Hepatitis B vaccine was adminis-
tered to all HBsAg negative patients. The vaccine is a 
recombinant hepatitis B surface antigen vaccine, given 
at 0, 1, 6 months intervals. Demographic data, such as 
age and number of blood transfusions were obtained 
from patient records. The children had received 9-85 
(median 30) units of blood transfusions at the time of 
sample collection. The patients were subjected to a full 
history taking including number of transfused units, a 
thorough clinical examination and biochemical investi-
gations. Written informed consent was obtained from 
the patients or their guardians. In addition, 100 healthy 
blood donors (75 males and 25 females) were used as a 
control group. 
Blood samples were withdrawn from the thalassemic 
patients and control group, collected into sterile tubes, 
allowed to clot at room temperature for 30 minutes and 
centrifuged. Sera were separated, alliquoted and stored 
at –20° C until used. For each patient, liver enzymes 
(alanine aminotransferase, aspartate aminotransferase) 
and total bilirubin were measured using Boehringer 
Mannheim reagents on chemistry auto-analyzer 
(Hitachi, Japan).
For each patient and control, HBV markers were 
measured by enzyme-linked immunoabsorbent assay 
(ELISA) techniques, including hepatitis B surface anti-
gen (HBsAg), antibody to hepatitis B core antigen (anti-
HBc antibody). Anti-HBc antibody was determined us-
ing Bio-Rad Fujirebio, Inc. Tokyo 116-0014 according 
to the manufacturer’s instructions. Hepatitis B virus sur-
face antigen (HBsAg) was determined using Diasorin 
S.P.A 13040 Saluggia (VC) Italy. All sera were screened 
using anti-HCV assays with third-generation commer-
cial ELISA microplate kits (DIA.PRO, Italy) accord-
ing to the manufacturer’s instructions. All sera positive 
for HCV Ab were retested by the recombinant immu-
noblot assay (RIBA) kits (HCV blot 3.0; Genelabs 
Diagnostics, Redwood City, CA, USA). Patients found 
positive with both ELISA and RIBA HCV Ab were 
considered infected with HCV.
Data were analyzed using the statistical package 
SPSS version 17.0 (IBM Corp, Armonk, NY, USA). 
Data were expressed as means and standard deviation 
(SD) and group differences were compared by using 
the t test and the Fisher exact test whenever applicable. 
Probability levels <.05 were considered significant
RESULTS
Two hundred thalassemic patients were tested. There 
were 111 (55.5%) males and 89(44.5%) females. The 
median age was 13 years (ranging from 11 months to 19 
years). Out of the 200 patients, 81 were anti-HCV posi-
tive by ELISA corresponding to a 40.5%. Among the 81 
anti-HCV positive patients, 39 (19.5%) were positive for 
HCV antibody by RIBA. 
Two hundred thalassemia patients were screened 
for anti-HBc antibody and HBsAg. Thirteen patients 
(6.5%) were positive for anti-HBc antibody. Of these 
200 thalassemic children, 58 patients were positive for 
HBsAg (29%). Seventeen patients (8.5%) were posi-
tive for both anti-HBc antibody and HBsAg (Table 1). 
Hence, serological evidence of HBV infection was de-
tected in 88 (44%) of the 200 patients. 
The results of the characteristics of patients with 
HBV and HCV infection were summarized in Tables 2 
and 3. The tables show the total serum bilirubin (TSB), 
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST) and alkaline phosphatase (ALP) levels in 
thalassemic patients. These biochemical parameters were 
significantly higher (P<0.0001 in post-transfused thalas-
semics with HBV and HCV compared to those without. 
Also the number of blood transfusions received by HBV 
and HCV positive thalassemia patients was significantly 
higher than that of hepatitis negative thalassemic pa-
tients (P<.05).
A number of risk factors that could be potentially as-
Table 1. Hepatitis HCv and HBv markers in thalassemic patients and healthy controls.
Patients (n=200) Control (n=100) P 
anti-HBc antibody 
alone 13 (6.5.0%) 4 (4%) not significant
HBsag alone 58 (29%) 0 (0%) <.0001
HBsag/anti-HBc 
antibody 17 (8.5%) 0 (0%) .001
HCv antibody 81 (40.50%) 3 (3%) <.0001
HCv antibody 
(riBa) 39 (19.5%) 0 (0%) <.0001
Fisher exact test; P significant at level <.05
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sociated with HCV infection, were compared between 
RIBA HCV-positive and HCV-negative patients (Table 
4). HCV seropositivity was significantly associated with 
an older age (P<.0001), increased number of blood trans-
fusion (P<.0001) and HBsAg seropositivity (P=.03). 
DISCUSSION
The frequency of HBsAg, anti-HBc antibody and anti 
HCV antibody positive cases in this study were at alarm-
ing high levels of 29.0%, 6.5% and 40.5% (19.5% by 
RIBA). respectively. It depicts an upward trend in the 
overall positivity both for HBsAg and anti-HCV anti-
bodies with increasing age, which in turn is associated 
with increasing transfusions and thereby the risk of ac-
quiring both infections.
Early and regular blood transfusion therapy in pa-
tients of b-thalassemia major decreases the complica-
tions of severe anemia and prolongs survival. This is 
particularly true in patients who are fortunate enough 
to receive adequate, regular iron-chelating therapy, and 
are therefore protected from organ damage by iron 
overload.11 However, if there is a breach in “safe blood 
transfusion”, these patients are confronted by new clini-
cal challenges, particularly in the form of transfusion-
transmitted diseases, especially HCV, HBV and HIV 
infections.12 The prevalence rate of seropositivity in-
creases with the number of transfusions units.13 This 
post-transfusion hepatitis has significantly contributed 
to morbidity in thalassemia.11
 In this study, the results show a high prevalence of 
hepatitis B and C in the sera of multi-transfused thalas-
semic children. The frequency of HBV markers were 
detected in 88 (44.%) of the subjects (29% of subjects 
were detected HBsAg and 6.5% of patients were posi-
tive for anti-HBc antibodies), which is higher than that 
observed for voluntary blood donors (4%). This figure 
was in accordance with the high incidence observed in 
similar groups of multi-transfused thalassemic patients 
from India (56%).14 This is higher than that observed in 
a study by Khakhkhar and Joshi who found that 6.6% 
of thalassemic patients were positive for HBsAg.15 A 
study by Sing had shown the prevalence 5.7% of HBsAg 
and 20% of anti-HBc positive among multi-transfused 
thalassemic children.16 The lower frequency of HBsAg 
of 1.5% to 8.4% were reported in other studies.17-20 In a 
very recent study from India12 the prevalence of transfu-
sion- transmitted infections such as HCV, and HBsAg 
was respectively 45% and 2%. 
Diagnosis of thalassemia is usually late in most chil-
dren and blood transfusion is started prior to establish-
ment of diagnosis or administration of HBV vaccine. 
HBsAg and anti-HBc antibody screening reduces, but 








not significantb   Male 42 (51.9%) 69 (58.0%)
   Female 39 (48.1%) 50 (42.0%)
age (years) 14.98 (3.05) 9.47 (4.02) .001
TSB (mg/dl) 1.8 (0.4) 0.78 (0.2) <.0001
aST (u/l) 39.2 (7.4) 23.4 (4.5) <.0001
alT (u/l) 38.1 (8.2) 24.3 (3.2) <.0001
alP (u/l) 241.4 (47.1) 145 (10.3) <.0001
Blood transfusion 
(units) 76.33 (63.0) 35.45 (44.0) <.0001
at test bFisher exat test. TSB= total serum bilirubin, aST=aspartate aminotransferase,alT=alanine aminotransferase, 
alP=alkaline phosphatase. 








not significantb   Male 64 (57.1%%) 47 (53.4.0%)
   Female 48  (42.9%) 41 (46.6.0%)
age (years) 7.65 (3.05) 15.36 (4.02) <.0001
TSB (mg/dl) 0.76 (0.3) 1.90 (0.9) <.0001
aST (u/l) 23.55 (5) 33.34 (8.3) <.0001
alT (u/l) 25.67 (4.7) 37.2 (9.1) <.0001
alP (u/l) 153.5 (14.5) 234.43 (171) <.0001
Blood transfusion 
(units) 23.52 (64) 59.27 (44) <.0001
at test bFisher exat test. TSB= total serum bilirubin, aST= aspartate aminotransferase,alT=alanine aminotransferase, 
alP= alkaline phosphatase. 
Table 4. Comparison of risk factors between riBa HCv positive and negative 
thalassemic patients by univariate analysis.
RIBA anti HCV 
positive (n=39)
RIBA anti HCV 
negative (n=161) P
age (years) 15.9 (3.4) 11.4 (5.6) <.0001
HBsag positivity 
(%) 17 (43.6) 41 (25.5) .03
Blood transfusion 
(units) 77.37 (66.5) 34.5 (45) <.0001
values are mean and standard deviation.
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does not abolish the occurrence of post-transfusion 
hepatitis B.21 The incidence of hepatitis decreased signif-
icantly after hepatitis B vaccination and donor screen-
ing program but these patients until now are prone to 
liver infection due to unknown or idiopathic risk fac-
tors.22 
The most common cause of post-transfusion hepa-
titis is HCV.23 Cross-sectional studies 10 years ago on 
the prevalence of HCV infection in thalassemic patients 
ranged from 4% to 85%.9 The reason for this wide range 
can be due to differences in the type and sensitivity of 
tests and also to differences in the total prevalence of se-
lected population.17 In the present study, the prevalence 
of HCV among voluntary blood donors was 3%, and 
40.5% of our thalassemic patients showed anti-HCV 
positivity. This is a relatively high percentage, keeping 
in mind that all the donated blood is regularly screened 
for HCV at all thalassemic centers in Egypt. However, 
this figure was lowered upon confirmation of anti HCV 
by RIBA to 19.5%. In different parts of the world the 
prevalence of HCV infection in thalassemic patients dif-
fers: in India it is 16.7%,8 and in Malaysia 22.4%,24 and 
Lebanon 14%.20 There are many reasons for lower prev-
alence, including awareness about hepatitis C and other 
blood-borne diseases indicating more advanced blood 
safety. On the other hand, some reports from Saudi 
Arabia infection was 63%,10 in Pakistan 60%,25 and in 
Italy 85%,26 much higher figures than that of the cur-
rent study. There is a great variation of the prevalence 
Table 5. incidence of Hepatitis viral infection from the region and from other parts of the world.





iran 2006 732 1.5 eliSa 19.3 eliSa,riBa 17
india 2001 102 56 eliSa 21.0 eliSa 14
india 2006 90 6.6 eliSa ---- ----- 15
india 2003 70 5.7 eliSa,PCr ----- ----- 16
Pakistan 1995 35 ---- ----- 60.0 eliSa 25
Pakistan 2005 86 8.4 eliSa 56.8 eliSa 18
Turkey 2006 399 0.8 eliSa 4.5 eliSa 19
Malaysia 1999 85 2.4 eliSa 22.4 eliSa 24
italy 1992 152 8.0 eliSa 47.0 eliSa,riBa 29
italy 1998 1481 ---- ---- 85.2 eliSa 26
Bahrain 1995 242 ---- ----- 40.0 eliSa 31
lebanon 2002 395 --- --- 14.0 eliSa,PCr 20
Taiwan 1996 61 --- --- 43.0 eliSa,PCr 28
rate of HCV in thalassemic patients among different 
parts of the world. In all these countries the donor’s 
blood is routinely screened for HCV. It is a known fact 
that HCV infection is most probably related to thal-
assemic patients’ treatment.27 Thalassemic patients 
may acquire hepatitis C through the administration of 
HCV-infected blood collected during the donor win-
dow period. This is one reason in thalassemic children 
because the risk due to drug abuse and sexual activity 
are not present. The incidence of hepatitis viral infec-
tion from our region and from other parts of the world 
is summarized in Table 5. 
Ni and colleagues in United States studied 61 
multi-transfused thalassemic children prospectively 
for 4 years. The results showed that in these children 
26/61 (43%) contracted HCV.28 In another study 
Cacopardo and colleagues in Germany tested the 
serum of 152 Sicilian multi-transfused subjects for 
anti-HCV antibodies. It showed 47% positivity for 
anti-HCV antibodies.29 This high incidence is also 
reported by other studies from some Arabic countries 
who found an HCV infection rate of 33% in Kuwait30 
and 40% in Bahrain.31 In our study, Anti-HCV anti-
body positivity was significantly higher with increased 
number of blood transfusion. It was observed in other 
studies that the number of blood transfusions received 
by anti-HCV antibody positive thalassemia patients 
was significantly higher than that of anti-HCV anti-
body negative thalassemic patients.12,28,32 
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The results of our study showed that the mean age 
for positive HCV antibody was significantly higher 
than negative HCV antibody. This result had been 
expected due to more exposure to HCV infection 
due to recurrent blood transfusion. Our observations 
strongly indicated the blood transfusion as the main 
risk factor for HCV infection acquisition among thal-
assemic patients, and confirmed the marked efficacy 
of donor screening in the prevention or mitigation 
of viral transmission. The cohort studies from Italy33 
and USA22 have also documented the effectiveness 
of blood donor screening. The older the patient, the 
higher the incidence of blood transfusion; this in-
creases the incidence of HCV infection and the posi-
tivity of HBsAg. Therefore, it is important to provide 
safe blood to reduce the incidence of HCV infection 
in thalassemic population.
In our study, a high prevalence of HCV seroposi-
tivity was observed. Although our patients were usual-
ly transfused at the thalassemia management center in 
Mansoura university hospitals, where pre-transfusion 
screening of the transfused is regularly performed. 
However, it was learned during interview of the pa-
tients’ parents that in almost all instances, the patients 
did get transfused with blood from some other cen-
ters, where pre-transfusion HCV antibody screening 
was not guaranteed. Furthermore, the parents of most 
of our patients were not aware of the importance of 
HCV antibody screening of transfused blood.
Frequent transfusion in peripheral centers may 
contribute to HBV and HCV infection in thalassemic 
patients as it is strongly indicated that blood transfu-
sion is the main risk factor for HCV infection acqui-
sition among thalassemic patients, especially through 
the administration of HCV-infected blood collected 
during the donor window period.34 This may occur 
because of the lack of regular validation of these pe-
ripheral centers that offering transfusion services. The 
marked efficacy of donor screening in the prevention 
or mitigation of viral transmission is confirmed and it 
seems that applying refined methods, more sensitive 
laboratory screening techniques, and assured qual-
ity control measures, in addition to appropriate and 
timely protocols for management of infected patients 
are likely to be the most useful strategies.17
In conclusion, we have shown a high frequency of 
hepatitis B and C infection in a cohort of Egyptian 
thalassemic patients undergoing regular transfusion 
therapy in Mansoura University Hospitals and cen-
ters. It is apparent that late diagnosis and frequent 
transfusion in peripheral centers contribute to HBV 
and HCV infection in these patients. However, ef-
forts should be made to identify the real reasons for 
the reported higher prevalence of HCV in the current 
study, which might include comparison of ELISA kits 
of different manufacturers, rigid implementation of 
quality control measures while testing and use of more 
specific and sensitive testing for HCV. 
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